FDA mulls compounding for peptides previously flagged over safety risks BioSpace The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Prohibited peptide and unapproved drug in supplements BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News